Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic

Geneva, Switzerland, and Nantes, France, 26 SEPTEMBER 2017 – Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of two commercial license agreements (CLAs) that provide OSE with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform™. The agreements are designed to support the advancement of the clinical development of OSE-172 (Effi-DEM), OSE’s new generation immune myeloid checkpoint inhibitor, as well as OSE-703 (Effi-3), OSE’s cancer immunotherapy, which is a cytotoxic monoclonal antibody targeting the IL-7 receptor.

“Our work with Selexis has been instrumental in advancing our investigational therapeutic candidates toward clinical development,” said Alexis Peyroles, chief operating officer of OSE Immunotherapeutics. “OSE and Selexis are focused on quickly advancing delivery of treatment options to patients facing life-threatening diseases. It’s exciting to watch the evolution of our relationship with Selexis, knowing the impact their technology is having on our research and development activities.”

Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

A new generation immune checkpoint inhibitor, OSE-172 (Effi-DEM) is a monoclonal antibody targeting SIRP-α, expressed on suppressive myeloid cells involved in the tumor microenvironment. As selective antagonist of SIRP-α, OSE-172 transforms the tumour microenvironment by blocking suppressor cells and activating anti-tumour effector cells. OSE-172 is planned to enter Phase 1/2 clinical phase in 2018.

OSE-703 (Effi-3) is a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7, cytotoxic for human cells expressing CD127. Under a research collaboration with Memorial Sloan Kettering Cancer Center, the cancer immunotherapy is in preclinical studies for solid tumors with non-small cell lung cancer (NSCLC) as the primary cancer model.

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 80+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, autoimmune diseases and transplantation. The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

###

FOR MORE INFORMATION

Web www.selexis.com

LinkedIn www.linkedin.com/company/selexis-sa

Twitter www.twitter.com/SelexisSA

Facebook www.facebook.com/SelexisSA